TY - JOUR
T1 - Acid-suppressive medications and risk of colorectal cancer
T2 - results from three large prospective cohort studies
AU - Babic, Ana
AU - Zhang, Xuehong
AU - Morales-Oyarvide, Vicente
AU - Yuan, Chen
AU - Khalaf, Natalia
AU - Khalili, Hamed
AU - Lochhead, Paul
AU - Chan, Andrew T.
AU - Ogino, Shuji
AU - Wolpin, Brian M.
AU - Wu, Kana
AU - Fuchs, Charles S.
AU - Giovannucci, Edward L.
AU - Stampfer, Meir J.
AU - Ng, Kimmie
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Cancer Research UK.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: Despite several plausible biological mechanisms linking proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) with colorectal tumorigenesis, their association with risk of colorectal cancer (CRC) has not been adequately assessed in prospective epidemiological studies. Methods: We evaluated the association of acid-suppressive medication use with CRC risk among 175,871 (PPI) and 208,831 (H2RA) participants from three large prospective cohort studies. Medication use was assessed at baseline and updated biennially. The association was evaluated using multivariate Cox proportional hazards regression models. Results: There was no significant association between baseline PPI use (hazard ratio (HR) = 0.89, 95% confidence interval (CI), 0.71–1.12) or PPI use after a lag of 8–10 years (HR = 1.12, 95% CI, 0.78–1.59) with CRC risk. We observed no significant association between H2RA use after a lag of 8–10 years and CRC risk (HR = 1.02, 95% CI, 0.81–1.28), while risk was lower for participants with baseline H2RA use (HR = 0.76, 95% CI, 0.60–0.95). Duration of PPI use or H2RA use was not associated with CRC risk (P-trend = 0.21 and 0.95, respectively). Conclusions: Among participants from three large prospective cohorts, use of PPI or H2RA was not associated with higher risk of colorectal cancer.
AB - Background: Despite several plausible biological mechanisms linking proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) with colorectal tumorigenesis, their association with risk of colorectal cancer (CRC) has not been adequately assessed in prospective epidemiological studies. Methods: We evaluated the association of acid-suppressive medication use with CRC risk among 175,871 (PPI) and 208,831 (H2RA) participants from three large prospective cohort studies. Medication use was assessed at baseline and updated biennially. The association was evaluated using multivariate Cox proportional hazards regression models. Results: There was no significant association between baseline PPI use (hazard ratio (HR) = 0.89, 95% confidence interval (CI), 0.71–1.12) or PPI use after a lag of 8–10 years (HR = 1.12, 95% CI, 0.78–1.59) with CRC risk. We observed no significant association between H2RA use after a lag of 8–10 years and CRC risk (HR = 1.02, 95% CI, 0.81–1.28), while risk was lower for participants with baseline H2RA use (HR = 0.76, 95% CI, 0.60–0.95). Duration of PPI use or H2RA use was not associated with CRC risk (P-trend = 0.21 and 0.95, respectively). Conclusions: Among participants from three large prospective cohorts, use of PPI or H2RA was not associated with higher risk of colorectal cancer.
UR - http://www.scopus.com/inward/record.url?scp=85089537446&partnerID=8YFLogxK
U2 - 10.1038/s41416-020-0939-y
DO - 10.1038/s41416-020-0939-y
M3 - Article
C2 - 32541871
AN - SCOPUS:85089537446
SN - 0007-0920
VL - 123
SP - 844
EP - 851
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 5
ER -